Additionally, increased CAMK2 mRNA expression was associated with significantly worse distant metastasis free survival in luminal A (p = 0.016) and triple negative breast cancer (p = 0.006) subtypes in the additional 3,935 patient cohort, but not luminal B or Her-2 subtypes. Here, ERBB2 is linked to triple-negative breast carcinoma.